FINWIRES · TerminalLIVE
FINWIRES

Exxon Q1 Hydrocarbons Output Rises YoY Despite Middle East Disruptions

By

-- Exxon Mobil (XOM) Friday reported a year-over-year increase in its Q1 oil and gas production, as higher output from the Americas more than offset supply disruptions in the Middle East.

For the quarter ended March 31, the upstream segment's oil and gas output stood at 4.59 million barrels of oil equivalent per day, a rise from the previous year's 4.55 mboe/d but a decline from the prior quarter's 4.99 mboe/d.

Net production of crude oil, natural gas liquids, bitumen, and synthetic oil was up year over year to 3.3 million barrels per day from 3.1 mmbbls/d, as higher output from the US, Canada and other American regions offset declines in Asia. Q1 output, however, was down versus the previous quarter's 3.5 mmbbls/d.

Net natural gas production came in lower at 7.8 million cubic feet per day, relative to year-ago levels of 8.5 mcf/d, largely due to lower Asian output. Q1 production was also down versus Q4's 8.7 mcf/d.

During the period, the company noted that Guyana achieved a record quarterly production of more than 900,000 gross barrels of oil per day, but the Middle East conflict negatively impacted overall output levels.

Golden Pass LNG, a joint venture between QatarEnergy and ExxonMobil, achieved first production from Train 1 at the end of March, Exxon said, resulting in a 5% year-over-year increase in US exports.

The company posted a decline in Q1 refinery throughput, primarily due to reduced processing in Europe and Asia. Throughput totaled 3.5 mmbbls/d in Q1, compared with 3.8 mmbls/d a year ago and 4.1 mmbbls/d a quarter earlier.

Nonetheless, energy product sales grew year over year to 5.6 mmbbls/d from 5.3 mmbbls/d, as higher US sales more than offset a drop in non-US volumes. Except for heating oils, kerosene, and diesel, all other energy products logged corresponding sale increases.

Q1 sales, however, were lower than Q4's 5.8 mmbbls/d, due to scheduled maintenance and Middle East disruptions, the company said.

Chemical product sales totaled 5.4 million tons in Q1, up versus 4.8 mmt a year earlier, but down compared with the previous quarter's 5.7 mmt.

Special product sales also grew to 1.98 mmt in Q1, versus 1.94 mmt in the prior year and 1.92 in the previous quarter, with high-value products achieving a record sales volume, according to the report.

Related Articles

Research

Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.

$INCY
Australia

GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease

GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%

$GSK
International

ISM US Manufacturing Index Indicates Steady Expansion in April

The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.